Drug Trial Radar · NCT01460693
Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia
Last checked: Nov 19, 2026Latest source record: Apr 24, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
814
Actual
Start
Aug 2008
Primary completion
Mar 7, 2018
Study completion Mar 7, 2018
Sponsor
- Lead sponsor
- Newcastle UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Newcastle-upon-Tyne Hospitals NHS Trust; Bristol-Myers Squibb; Institute of Cancer Research, United Kingdom; Hammersmith Hospitals NHS Trust
- First posted
- Oct 27, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Imatinib 400mg daily is the current NICE-approved standard treatment for newly diagnosed Chronic Myeloid Leukaemia (CML). 5 yr follow up of CML patients treated in this way indicates an 89% probability of progression-free survival. Imatinib is not tolerated or effective in some patients however, and a proportion of patients become resistant to the drug. SPIRIT 2 study aims to establish whether a new drug, dasatinib, is superior to imatinib in terms of event free survival and therefore will be an effective first-line therapy for newly-diagnosed CML patients. This study will also provide crucial long-term survival, quality of life and health economic data to assist health care providers and managers to determine the most cost-effective drug therapy for CML.
Conditions
- Myeloid Leukemia, Chronic, Chronic Phase
Interventions
ImatinibDrug
Oral Imatinib 100mg daily
DasatinibDrug
Oral Dasatinib 100mg daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- 5-year event free survivalTime frame: ongoing throughout study (5 years)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Freeman Hospital
Newcastle upon Tyne, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.